Association between beta-blocker atenolol use and prostate cancer upgrading in active surveillance.

ABSTRACT:

Objectives

The objective of this study is to investigate the association between the use of beta-adrenergic antagonist atenolol and risk of pathologic upgrade in patients on active surveillance, considering growing literature implicating adrenergic innervation with disease progression mediated through beta-adrenergic signalling.

Patients and methods

Men with low-risk or favourable intermediate-risk prostate cancer who were placed on an active surveillance protocol between 2006 and 2020 across three diverse urban hospitals were included. Exposure was duration of atenolol use, and outcome was pathologic grade group upgrading (to GG ≥ 3) on final prostate biopsy. Cox proportional hazard regression models were used to determine the associations between atenolol use and risk of u

SUBMITTER: Zahalka AH 

PROVIDER: S-EPMC11557265 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature